Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:15867340rdf:typepubmed:Citationlld:pubmed
pubmed-article:15867340lifeskim:mentionsumls-concept:C0029016lld:lifeskim
pubmed-article:15867340lifeskim:mentionsumls-concept:C0079427lld:lifeskim
pubmed-article:15867340lifeskim:mentionsumls-concept:C0020793lld:lifeskim
pubmed-article:15867340lifeskim:mentionsumls-concept:C1325410lld:lifeskim
pubmed-article:15867340pubmed:issue9lld:pubmed
pubmed-article:15867340pubmed:dateCreated2005-5-3lld:pubmed
pubmed-article:15867340pubmed:abstractTextFps/Fes proteins were among the first members of the protein tyrosine kinase family to be characterized as dominant-acting oncoproteins. Addition of retroviral GAG sequences or other experimentally induced mutations activated the latent transforming potential of Fps/Fes. However, activating mutations in fps/fes had not been found in human tumors until recently, when mutational analysis of a panel of colorectal cancers identified four somatic mutations in sequences encoding the Fps/Fes kinase domain. Here, we report biochemical and theoretical structural analysis demonstrating that three of these mutations result in inactivation, not activation, of Fps/Fes, whereas the fourth mutation compromised in vivo activity. These results did not concur with a classic dominant-acting oncogenic role for fps/fes involving activating somatic mutations but instead raised the possibility that inactivating fps/fes mutations might promote tumor progression in vivo. Consistent with this, we observed that tumor onset in a mouse model of breast epithelial cancer occurred earlier in mice targeted with either null or kinase-inactivating fps/fes mutations. Furthermore, a fps/fes transgene restored normal tumor onset kinetics in targeted fps/fes null mice. These data suggest a novel and unexpected tumor suppressor role for Fps/Fes in epithelial cells.lld:pubmed
pubmed-article:15867340pubmed:languageenglld:pubmed
pubmed-article:15867340pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867340pubmed:citationSubsetIMlld:pubmed
pubmed-article:15867340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867340pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:15867340pubmed:statusMEDLINElld:pubmed
pubmed-article:15867340pubmed:monthMaylld:pubmed
pubmed-article:15867340pubmed:issn0008-5472lld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:YenI HIHlld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:JiaZongchaoZlld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:MullerWilliam...lld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:GreerPeter...lld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:SangrarWaheed...lld:pubmed
pubmed-article:15867340pubmed:authorpubmed-author:ZirgniblRalph...lld:pubmed
pubmed-article:15867340pubmed:issnTypePrintlld:pubmed
pubmed-article:15867340pubmed:day1lld:pubmed
pubmed-article:15867340pubmed:volume65lld:pubmed
pubmed-article:15867340pubmed:ownerNLMlld:pubmed
pubmed-article:15867340pubmed:authorsCompleteYlld:pubmed
pubmed-article:15867340pubmed:pagination3518-22lld:pubmed
pubmed-article:15867340pubmed:dateRevised2009-11-19lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:meshHeadingpubmed-meshheading:15867340...lld:pubmed
pubmed-article:15867340pubmed:year2005lld:pubmed
pubmed-article:15867340pubmed:articleTitleAn identity crisis for fps/fes: oncogene or tumor suppressor?lld:pubmed
pubmed-article:15867340pubmed:affiliationDivision of Cancer Biology and Genetics, Queen's University Cancer Research Institute, Queen's University, Kingston, Ontario, Canada.lld:pubmed
pubmed-article:15867340pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:15867340pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed
pubmed-article:15867340pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:14159entrezgene:pubmedpubmed-article:15867340lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:15867340lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867340lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:15867340lld:pubmed